Product image
InVivoMAb anti-mouse CD8beta (Lyt 3.2)
BE0223
ApplicationsImmunoFluorescence, Neutralisation/Blocking, Other Application
Product group Antibodies
ReactivityMouse
Overview
- SupplierBio X Cell
- Product NameInVivoMAb anti-mouse CD8beta (Lyt 3.2)
- Delivery Days Customer7
- ApplicationsImmunoFluorescence, Neutralisation/Blocking, Other Application
- CertificationResearch Use Only
- ClonalityMonoclonal
- Clone ID53-5.8
- Concentration4-11 mg/ml
- Estimated Purity>95%
- HostRat
- IsotypeIgG1
- ReactivityMouse
- Storage Instruction2°C to 8°C
- UNSPSC12352203
References
- Activated Brain Endothelial Cells Cross-Present Malaria Antigen. Howland SW et al., 2015 Jun, PLoS PathogRead more
- NKT cell-targeted vaccination plus anti-4-1BB antibody generates persistent CD8 T cell immunity against B cell lymphoma. Kobayashi T et al., 2015 Mar, OncoimmunologyRead more
- Immunosurveillance and therapy of multiple myeloma are CD226 dependent. Guillerey C et al., 2015 May, J Clin InvestRead more
- Targeting CD73 enhances the antitumor activity of anti-PD-1 and anti-CTLA-4 mAbs. Allard B et al., 2013 Oct 15, Clin Cancer ResRead more
- Radiotherapy increases the permissiveness of established mammary tumors to rejection by immunomodulatory antibodies. Verbrugge I et al., 2012 Jul 1, Cancer ResRead more
- Direct in vivo evidence of CD4+ T cell requirement for CTL response and memory via pMHC-I targeting and CD40L signaling. Ahmed KA et al., 2012 Aug, J Leukoc BiolRead more
- Self-class I MHC molecules support survival of naive CD8 T cells, but depress their functional sensitivity through regulation of CD8 expression levels. Takada K et al., 2009 Sep 28, J Exp MedRead more